Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Ola A. Harb

Ola A. Harb

Zagazig University, Zagazig, Egypt

Title: Prognostic and clinic-pathological significances of SCF and COX-2 expression in Prostatic adenocarcinoma

Biography

Biography: Ola A. Harb

Abstract

Background;

Stem cell factor (SCF) is an inflammatory cytokine that specific to the c-KIT receptor which is a tyrosine kinase receptor belonging to the type III receptor tyrosine kinase (RTK) family. COXs are key enzymes responsible for the production of prostaglandins from arachidonic acid.

The aim of our study; is to investigate the prognostic and clinic-pathological significance of SCF and COX-2 expression in prostatic adenocarcinoma and in chronic Prostatitis a trial to emphasize association between chronic prostatitis a risk factor for cancer progression.

Methods: SCF and COX-2 expression were evaluated in tissue biopsies that are retrieved from 50 cases of prostatic adenocarcinoma, 20 cases of chronic prostatitis and 10 cases of nodular prostatic hyperplasia using immunohistochemistry, patients that were followed up for 5 years. The relationship between their levels of expressions, clinicopathological follow up and prognostic criteria were studied.

Results: SCF expression in PC was positively correlated with Advanced patient age (p=<0.001) , high level of PSA (p=0.010), higher Gleason score (p=0.011), recurrence of the tumor after successful therapy, disease free survival and overall survival (p<0.001). COX-2   expression in PC was positively correlated with Advanced patient age (p=<0.001) , high level of PSA (p=0.016), advanced D'Amico risk group (p= 0.038) higher incidence of tumor relapse, worse disease free survival and overall survival (p<0.001).

Conclusion: High levels of expression of SCF and COX-2 are associated with cancer progression and are markers of poor prognosis in PC patients.

Keywords: SCF, COX-2, prostatic adenocarcinoma, immunohistochemistry; prognosis